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ABSTRACT
Background: Reactivation of human herpesvirus (HHV)
infection, especially HHV-6, has been observed in
patients with drug-induced hypersensitivity syndrome
(DIHS). In toxic epidermal necrolysis (TEN) and
Stevens–Johnson syndrome (SJS), the relevance of
HHV infection to the symptoms is unclear.
Methods: Patients with a diagnosis of DIHS (n = 7),
TEN (n = 5) and SJS (n = 4) were included in the
present study. These patients were evaluated for
the presence of active HHV-6, HHV-7 and cytomegalo-
virus (CMV) infections by serological tests and
polymerase chain reaction with blood.
Results: More than 3 weeks after the onset of DIHS,
HHV-6 serological tests revealed a remarkable rise in
IgG antibodies in six patients, including one treated
without steroids. Human herpesvirus-6 DNA was
detected in blood from three patients. In one patient
with DIHS, reactivation of CMV was shown without
reactivation of HHV-6, whereas in three patients
anti-CMV IgG antibodies increased after the rise of
anti-HHV-6 IgG antibodies. Anti-HHV-7 IgG anti-
bodies did not show remarkable rises in any of these
patients. As for patients with TEN and SJS, anti-HHV-6,
anti-HHV-7 and anti-CMV IgG antibodies showed no
significant increase, except for one patient in whom
anti-HHV-6 and anti-HHV-7 IgG antibodies increased,
but not more than 1 : 160, after steroid therapy.
Human herpesvirus-6 DNA was not detected in the
blood of those patients.
Conclusions: Human herpesvirus-6 reactivation in
patients with DIHS is not due to non-specific reactiva-
tion induced by steroid therapy, but to events specific
to DIHS. We hypothesize that DIHS may occur as a
result of reactivation of HHV, especially HHV-6,
accompanied with an allergic reaction to drugs, fol-
lowed by a substantial immune response to the virus
that is probably responsible for visceral involvement.
Key words: cytomegalovirus, drug-induced hyper-
sensitivity syndrome, human herpesvirus-6, Stevens–
Johnson syndrome, toxic epidermal necrolysis.
INTRODUCTION
The association between viral infection and drug erup-
tion has been well documented in infectious mono-
nucleosis caused by Epstein–Barr virus (EBV), in which
ampicillin rash is frequently observed. In addition to EBV,
human herpesvirus (HHV)-6 and cytomegalovirus (CMV;
HHV-5) have also been reported as causative viruses of
infectious mononucleosis-like syndrome.1,2
Recently, active infection of HHV-6 has been reported
in drug-induced hypersensitivity syndrome (DIHS) or drug
reaction with eosinophilia and systemic symptoms
(DRESS).3–6 Cytomegalovirus was also detected in a few
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patients with DIHS.7 Drug-induced hypersensitivity syn-
drome is a serious adverse systemic reaction that usually
occurs within 3–6 weeks from the start of treatment. It is
characterized by generalized exanthematous eruption,
high fever, liver dysfunction, lymphoadenopathy and
marked leukocytosis accompanied by eosinophilia and
atypical lymphocytosis,8–11 occurring after administration
of, particularly, anticonvulsants and salicylates. Those
manifestations are also observed during infectious
mononucleosis.
Toxic epidermal necrolysis (TEN) and Stevens–
Johnson syndrome (SJS) also present as a serious drug-
induced rash with skin excoriation, necrotic lesions on
mucous membranes and visceral involvement.12 In con-
trast with DIHS, TEN and SJS are not usually associated
with lymphoadenopathy or with marked leukocytosis and
atypical lymphocytes. Although an increase in antibodies
to herpes simplex virus (HSV) is observed in some SJS
patients, the active infection of HHV-6 and CMV has not
been studied in TEN and SJS. Therefore, the relevance of
HHV infection to these diseases has not been elucidated.
In the present study, we examined HHV infection in
patients with DIHS, TEN and SJS to clarify the involvement
of HHV infection in the pathogenesis of these diseases.
METHODS
Patients
Patients with a diagnosis of DIHS (seven males), TEN
(three males and two females) and SJS (two males and
two females) were examined. The age range was
14–77 years in DIHS, 10–73 years in TEN and
5–54 years in SJS. The diagnosis of TEN and SJS was
based on the criteria proposed by Bastuji-Garin et al.13
All patients with TEN showed epidermal detachment of
more than 30% of their body surface. The diagnosis
of  DIHS was based on the late onset (more than
2 weeks) from the start of drug therapy, the presence of
widespread exanthematous eruption, high fever, liver
dysfunction (alanine aminotransferase >50 IU/L) and
leukocytosis (>11 000 /µL) accompanied by atypical
lymphocytosis and/or eosinophilia (>600/µL).
Virological investigations were performed to examine
the possibility of a viral infection. Samples of patients’
sera were tested for EBV, HSV, HHV-6, HHV-7 and CMV.
The sera were obtained between 2 and 11 days after the
onset of the diseases for the first test and beyond day 21
for further tests. Sera were tested for anti-HHV-6 and
anti-HHV-7 antibodies by fluorescent assay and by
enzyme immunoassay (EIA) for anti-EBV, ant-HSV and
anti-CMV antibodies. An increase of fourfold or more of
titers between the samples was regarded as significant.
The polymerase chain reaction (PCR) procedure was
used to detect HHV-6, HHV-7 and CMV DNA in sera and
peripheral blood mononuclear cells (MNC) from five
patients with DIHS and eight patients with TEN and SJS.
The HHV-6 and CMV load in some of those sera and
MNC was also quantified using real-time PCR.14,15
RESULTS
The drugs responsible and the time between the start of
drug therapy and eruption are given in Table 1. In many
cases, the causative drug of DIHS was an anticonvulsant
(three carbamazepine and two phenytoin). Mexiletine,
an anti-arrhythmic agent, and cyanamide, an alcohol-
deterrent agent, also caused DIHS. As for TEN and SJS,
the drug responsible was an anticonvulsant in two
patients, cold medicine or acetoaminophen in three
patients and omeprazole, an anti-ulcerative agent, in
one patient. In two patients, the drugs responsible could
not be determined because several drugs, including
some antimicrobials and anti-inflammatory agents, were
administered concomitantly. Six of seven patients with
DIHS developed skin eruption after more than 4 weeks
of therapy. All patients with TEN and SJS developed skin
eruption within 3 weeks from the start of therapy.
All patients were cured after hospitalization and the
treatments administered are given in Table 1. All patients
with DIHS, except for one (case 2), were treated with
systemic corticosteroids. Eight patients, including two
DIHS patients, recovered after 500–1000 mg/day methyl-
prednisolone pulse therapy for 3 consecutive days. A
10-year-old boy with TEN was treated with 30 mg/kg
bodyweight methylprednisolone per day for 3 consecu-
tive days and 1 mg/kg bodyweight per day cyclosporine.
In patients with TEN and SJS, conservative skin dressings
were used.
All patients with DIHS showed substantial leuko-
cytosis (16 500–38 720/µL) with atypical lymphocytosis
(253–3963/µL) and eosinophilia (660–12 930/µL) before
corticosteroid therapy (Table 2). In contrast, leukocytosis
was not observed in any patient with TEN and in only
one patient with SJS before therapy. Only one patient
(case 12) with TEN showed mild eosinophilia (739/µL).
In one patient with TEN (case 11), mild atypical lympho-
cytosis (92/µL) was observed after steroid pulse therapy.
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Table 1 Clinical characteristics of the patients
Diagnosis/patient no. Age (years)
/sex
Drug responsible Delay† 
(days)
Steroid therapy Cyclosporine 
therapy‡
Drug-induced hypersensitivity syndrome
1 16/M Carbamazepine 28 BMS 12 mg/day –
2 55/M Phenytoin 32 – –
3 64/M Phenytoin 28 mPSL 500 mg/day –
4 77/M Carbamazepine 34 PSL 60 mg/day –
5 53/M Mexiletine 53 PSL 10 mg/day –
6 46/M Cyanamide 50 BMS 8 mg/day –
7 14/M Carbamazepine 16 mPSL 1000 mg/day –
Toxic epidermal necrolysis
8 17/M Cold medicine 2 BMS 8 mg/day –
9 73/M ND§ 4–14 mPSL 500 mg/day –
10 56/M ND§ 3–20 mPSL 1000 mg/day –
11 38/M Acetaminophen 1 mPSL 1000 mg/day –
12 35/F Omeprazole 9 mPSL 1000 mg/day –
13 10/F Cold medicine 1 mPSL 500 mg/day 1 mg/kg per day
Stevens–Johnson syndrome
14 42/F Carbamazepine 7 mPSL 500 mg/day –
15 30/M Phenobarbital 15 mPSL 1000 mg/day –
16 26/F Diaphenylsulfone 8 BMS 10 mg/day –
17 5/M Azithromycin 3 BMS 4 mg/day –
†Time (days) between the start of drug therapy and skin eruption.
§Many drugs were possibly responsible.
‡Maximum doses of steroids administered are shown.
BMS, betamethasone; PSL, prednisolone; mPSL, methylprednisolone; ND, not determined.
Table 2 Laboratory data of the patients
Diagnosis/patient no. Leukocytosis† Eosinophilia‡ Atypical lymphocyte§ Liver involvement*
Drug-induced hypersensitivity syndrome
1 + + ++ +++
2 + ++ +++ +++
3 +++ +++ + ++
4 + + + ++
5 ++ +++ + ++
6 +++ +++ ++ ++
7 +++ +++ +++ ++
Toxic epidermal necrolysis
8 – – – –
9 – – – ++
10 – – – –
11 – – + ++
12 – + – ++
13 – – – –
Stevens–Johnson syndrome
14 – – – +
15 – – – +
16 + – – –
17 – – – –
†White blood cell count (× 104/µL): –, <1.1; +, between 1.1 and <2; ++, between 2 and <3; +++, ≥ 3.
‡Eosinophils (/µL): –, < 600; + between 600 and <1000; ++, between 1000 and <3000; +++, ≥ 3000.
§Atypical lymphocytes (/µL): –, <90; +, between 90 and <500; ++, between 500 and <2000; +++, ≥ 2000.
*Alanine aminotransferase (IU/L): –, <50; +, between 50 and <100; ++, between 100 and <300; +++, ≥ 300.
In patient 11, atypical lymphocytosis was observed after steroid pulse therapy.
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Liver involvement was recognized in all DIHS patients
(alanine aminotransferase 202–596 IU/L) and in five of
10 patients with TEN and SJS (51–175 IU/L).
In the first serum samples from patients with DIHS, IgM
antibodies to HHV-6, HHV-7 and CMV were not
detected. In those samples, anti-HHV-6 and HHV-7 IgG
antibodies were 1 : 80 or less. However, more than
3 weeks after the onset of the disease, HHV-6 serological
tests revealed a marked rise (1 : 1280–1 : 10 240) of
IgG antibodies in six of seven patients with DIHS
 
Table 3 Reactivation of human herpesvirus (HHV)-6, HHV-7 and cytomegalovirus (CMV) in patients with drug-induced
hypersensitivity syndrome showing increase of specific antibodies to HHV-6, HHV-7 and CMV
Patient Days of the 
assay
HHV-6 HHV-7 CMV 
IgG IgM IgG IgM IgG IgM
1 12 <1 : 10 1 : 40 <1 : 10 1 : 80 0.52 32.9
27 1 : 80 1 : 5120 <1 : 10 1 : 160 0.8 29.9
41 1 : 20 1 : 1280 ND ND 3.72 536
59 <1 : 10 1 : 1280 <1 : 10 1 : 160 2.04 128
2 8 <1 : 10 1 : 80 ND ND ND ND
23 ND 1 : 1280 ND ND ND ND
42 ND 1 : 5120 ND ND ND ND
3 15 <1 : 10 1 : 40 <1 : 10 1 : 160 0.1 15.6
49 <1 : 10 1 : 80 <1 : 10 1 : 80 1.14 120
4 19 <1 : 10 1: 40 ND ND 0.26 40.1
36 <1 : 10 1 : 5120 ND ND 0.53 42.8
74 <1 : 10 1 : 320 ND ND 0.31 539
5 47 <1 : 10 1 : 5120 ND ND ND ND
6 6 <1 : 10 1 : 10 <1 : 10 1 : 20 ND 7.4
27 ND 1 : 2560 <1 : 10 1 : 80 0.8 10.4
65 ND ND ND ND ND 67.7
132 ND 1 : 1280 ND 1 : 80 ND ND
7 10 <1 : 10 1 : 10 <1 : 10 1 : 80 0.38 < 2.0
19 <1 : 10 1 : 5120 <1 : 10 1 : 160 ND ND
58 <1 : 10 1 : 10 240 <1 : 10 1 : 160 0.21 < 2.0
Onset of the disease is day 1. ND, not done; –, not increased.
Human herpesvirus-6 and HHV-7 IgG values are fluorescent antibody titers. Cytomegalovirus antibody values correspond to enzyme
immunoassay units (U/mL).
Table 4 Reactivation of human herpesvirus (HHV)-6, HHV-7 and cytomegalovirus in patients with drug-induced hypersensitivity
syndrome showing viral DNA in blood mononuclear cells and in serum
Patient Day of 
the assay
Viral DNA in MNC (copies/106 cells) Viral DNA in serum (copies/106 cells) 
HHV-6 HHV-7 CMV HHV-6 HHV-7 CMV
1 12 < 20 – – – – –
20 ND ND ND + – –
27 73 – – – – –
41 49 – – – – +
59 < 20 2.5 × 102 ND ND ND –
3 15 ND ND ND ND ND ND
29 ND ND ND ND ND 9.7 × 103 
copies/mL
4 19 ND ND ND – – –
36 ND ND ND – – +
74 ND ND ND – – –
6 21 9 × 102 – – ND ND ND
7 10 3.5 × 105 – – ND ND ND
CMV, cytomegalovirus; MNC, mononuclear cell; ND, not done; –, not detected; +, detected by polymerase chain reaction.
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(Table 3). Anti-HHV-6 IgM antibodies were detected in
only one of the six patients after an increase in anti-
HHV-6 IgG antibodies. In the remaining patient with
DIHS (case 3),7 a serological test for CMV showed
increases in IgM and IgG antibodies 7 weeks after the
onset of the disease without an increase in anti-HHV-6
IgG antibodies. In three patients (cases 1, 4 and 6), anti-
CMV IgG antibodies also increased after the increase in
anti-HHV-6 IgG antibodies. Anti-HHV-7 IgG antibodies
did not show any significant increases in any of the
patients with DIHS.
Human herpesvirus-6 DNA was detected in the MNC
of three patients (cases 1, 6 and 7) 3 weeks after the
onset of the disease (Table 4). In case 7,16 quantitative
analysis of HHV-6 load showed as high as 3.5 × 105
copies per 106 cells. In case 1, HHV-6 DNA was detected
in the serum, followed by the appearance of CMV DNA in
serum obtained 2 weeks later. In this patient, HHV-7
DNA was also detected in MNC after HHV-6 DNA was
detected. In cases 1, 3 and 4, CMV DNA was detected in
sera.
As for patients with TEN and SJS, anti-HHV-6, HHV-7
and CMV IgM antibodies were all negative and the
IgG antibodies for those viruses showed low values
(anti-HHV-6 IgG 1 : ≤ 80, anti-HHV-7 IgG 1 : ≤ 160,
anti-CMV IgG < 2.0) during the course of the disease
(Table 5). In case 8, anti-HHV-6 IgG and anti-HHV-7
IgG antibodies showed increases within this range on day
69 (day 20 anti-HHV-6 IgG antibody 1 : 20, anti-HHV-7
IgG antibody 1 : ≤ 10; day 69 anti-HHV-6 IgG antibody
1 : 20, anti-HHV-7 antibody IgG 1 : 160). Human herpes-
virus-6 DNA was not detected in patients examined
except for one patient with TEN, in whom HHV-7 DNA
was detected in the MNC with atypical lymphocytosis.
Serological tests for EBV and HSV showed no IgM and
stable IgG titers in any patient with DIHS, TEN and SJS.
Hepatitis B virus in the sera and serological tests for
hepatitis C virus were negative in all patients.
DISCUSSION
The role of HHV-6 in the pathogenesis of DIHS has been
debated in recent years and it has not been clarified
whether active HHV-6 infection is specific to DIHS. It was
reported that patients who developed macropapular
exanthema due to drugs were not positive for HHV-6
DNA by PCR and by immunohistochemical analysis in
any exanthematous skin and peripheral blood lympho-
cytes.17 However, there have been no reports in which
HHV infection has been investigated in patients with TEN
and SJS.
Human herpesvirus-6 infection occurs in children
before 2 years of age. It is usually asymptomatic and
symptomatic primary infection induces exanthema
subitum. However, severe primary infection may cause
mononucleosis-like syndrome, hepatitis, meningo-
encephalitis and interstitial pneumonitis, mostly in
immunosuppressed patients, such as bone marrow
transplant recipients.
In sex of our seven DIHS patients, active HHV-6 infec-
tion was evidenced by a marked rise in anti-HHV-6 IgG
antibodies and, in one of patient, low titers of anti-HHV-6
IgM antibodies were detected, which could have been
due to either primary infection or reactivation. In all three
 
Table 5 Reactivation of human herpesvirus (HHV)-6, HHV-7 and cytomegalovirus in patients with toxic epidermal necrolysis
and Stevens–Johnson syndrome
Diagnosis Patient no. Increase of antibodies (IgG and IgM) Viral DNA in blood MNC (copies/106 cells) 
HHV-6 HHV-7 CMV HHV-6 HHV-7 CMV
TEN 8* + + – ND ND ND
9 – – – – – –
10 – – – – – –
11 – – – – Day 12, 
1.5 × 102 
–
12 – – – – – –
13 – – – – – –
SJS 14 – – – ND ND ND
15 – – – – – –
16 – – – – – –
17 – – – – – –
TEN, toxic epidermal necrolysis; SJS, Stevens–Johnson syndrome; MNC, mononuclear cells; ND, not done.
*Anti-HHV-6 IgG antibody 1 : 20 (day 20), 1 : 80 (day 69); anti-HHV-7 IgG antibody 1 : < 10 (day 20), 1 : 160 (day 69).
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patients in whom we investigated HHV-6 DNA in MNC by
PCR, the HHV-6 genome was detected. However, the
meaning of HHV-6 DNA in MNC is controversial when
the number of DNA copies is not high, because it can be
detected in more than 30% of healthy persons.18 In two of
the three patients with a positive result by PCR analysis,
the number of DNA copies in MNC was as high as
9 × 102 copies per 106 and 3.5 × 105 copies per 106
cells. As for the other patient with a rather low value of
HHV-6 DNA copies in MNC, HHV-6 DNA was also
detected in the serum. This indicated active replication of
HHV-6, because HHV-6 DNA is never detected in the
serum of healthy subjects.18 Therefore, these data seem
to indicate reactivation of HHV-6 in those patients.
Infection with other human β-herpesvirus, namely
HHV-7 and CMV, for which primary infection occurs, as
with HHV-6, in early childhood, was also investigated in
those DIHS patients. None of the patients examined
showed an increase of antibodies against HHV-7. How-
ever, HHV-7 DNA was detected in MNC on day 59
following HHV-6 DNA detection in one patient. This may
indicate that HHV-6 may have induced HHV-7 reactiva-
tion in the patient, because both HHV-6 and HHV-7
are  known to infect and reside in circulating CD4+
lymphocytes19 and HHV-7 reactivation has been reported
to trigger reactivation of HHV-6.20 In four patients
with  DIHS, reactivation of CMV was recognized. Three
showed an increase of anti-CMV IgG antibodies and
positive PCR results for CMV in the serum after reactiva-
tion of HHV-6. The remaining patient was positive for
the CMV genome in the serum without HHV-6 active
infection, although HHV-6 genome in blood was not
examined. These findings indicate that CMV infection
may contribute to the aggravation of symptoms of
DIHS in at least some patients. Otherwise, steroid
therapy may induce reactivation of CMV without any
contribution to the symptoms, although the role of
CMV reactivation after HHV-6 reactivation is not clear
in DIHS.
In nine patients with TEN and SJS, either IgG or IgM
antibodies for HHV-6, HHV-7 and CMV increased during
the course of the disease. In one patient with SJS, IgG
antibodies for HHV-6 and HHV-7 increased after steroid
therapy, but those values were not high. Human
herpesvirus-6 DNA was not detected in any of the eight
patients examined. Only one patient was positive for
HHV-7 DNA after steroid pulse therapy. Therefore, HHV
infection does not seem to play an important role in the
pathogenesis of TEN and SJS.
Regarding the relationship between HHV-6 reactiva-
tion and steroid therapy in patients with an adverse drug
reaction, this should be discussed because reactivation of
HHV has been reported in immunosuppressed patients
after transplantation.21 One of our patients with DIHS
showed HHV-6 reactivation despite the fact that he had
not received steroids or other immunosuppressive
therapy. In another patient, just 10 mg prednisolone had
been administered prior to the increase in anti-HHV-6
IgG antibodies. In addition, despite massive administra-
tion of corticosteroids, all patients with TEN and SJS
showed negative results for HHV-6 reactivation. Taken
together, these data indicate that HHV-6 reactivation in
patients with DIHS was not due to non-specific polyclonal
reactivation induced by steroid therapy, but to events
specific to DIHS.
It has not been elucidated how HHV-6 infection
contributes to the pathogenesis of DIHS. Although viral
infection may be responsible for the development of the
symptoms, the trigger of HHV-6 reactivation remains to
be clarified. Hypogammaglobulinemia was recognized in
some patients at the onset of DIHS.6,14,22 This may
indicate a disturbance of the immune system in those
patients, although it is known that some patients who are
administered anticonvulsants show hypogammaglobu-
linemia even without DIHS.23,24 Furthermore, it has been
reported that in patients with DIHS, metabolites of the
drugs generated through abnormal, detoxification path-
ways are cytotoxic or capable of disturbing the immune
system.25,26 The induction of antibodies to cytochrome
P450 components could be related to virus infection in
DIHS.6,27 In addition, many factors, such as positive patch
testing and the drug-induced lymphocyte stimulation test,
suggest an allergic mechanism in DIHS.26,28
Thus, we hypothesize that DIHS may occur as a result
of reactivation of HHV, especially HHV-6, accompanied
by an allergic reaction to drugs in patients whose immune
system has been affected by drugs. This may be followed
by a substantial immune response to the virus, which is
probably responsible for the visceral involvement, such as
liver dysfunction.
REFERENCES
1 Akashi K, Eizu Y, Sumiyoshi Y et al. Severe infectious
mononucleosis-like syndrome and primary human
herpesvirus 6 infection and in an adult. N. Engl. J. Med.
1993; 329: 168–71.
 
HHV INFECTION IN ADVERSE DRUG REACTION 29
2 Kano Y, Shiohara T. Current understanding of cyto-
megalovirus infection in immunocompetent individuals.
J. Dermatol. Sci. 2000; 22: 196–204.
3 Descamps V, Bouscarat F, Laglenne S et al. Human
herpesvirus 6 infection associated with anticonvulsant
hypersensitivity syndrome and reactive haemo-
phagocytic syndrome. Br. J. Dermatol. 1997; 137:
605–8.
4 Suzuki Y, Inagi R, Aono T et al. Human herpesvirus 6
infection as a risk factor for the development of severe
drug-induced hypersensitivity syndrome. Arch. Dermatol.
1998; 134: 1108–12.
5 Tohyama M, Yahata Y, Yasukawa M et al. Severe hyper-
sensitivity syndrome due to sulfasalazine associated with
reactivation of human herpesvirus 6. Arch. Dermatol.
1998; 134: 1113–17.
6 Descamps V, Valance A, Edlinger C et al. Association of
human herpesvirus 6 infection with drug reaction with
eosinophilia and systemic symptoms. Arch. Dermatol.
2001; 137: 301–4.
7 Aihara M, Sugita Y, Takahashi S et al. Anticonvulsant
hypersensitivity syndrome associated with reactivation
of cytomegalovirus. Br. J. Dermatol. 2001; 144:
1231–4.
8 Silverman AK, Fairlei J, Wong RC. Cutaneous and immu-
nologic reaction to phenytoin. J. Am. Acad. Dermatol.
1988; 18: 721–41.
9 Handfield-Jones SE, Jenkins RE, Whittaker SL et al. The
anticonvulsant hypersensitivity syndrome. Br. J. Dermatol.
1993; 129: 175–7.
10 Callot V, Roujeau J-C, Bagot M et al. Drug-induced
pseudolymphoma and hypersensitivity syndrome: Two
different clinical entities. Arch. Dermatol. 1996; 132:
1315–21.
11 Chopra S, Levell NJ, Cowley G et al. Systemic cortico-
steroids in the phenytoin hypersensitivity syndrome. Br. J.
Dermatol. 1996; 134: 1109–12.
12 Roujeau JC, Stern RS. Severe adverse cutaneous
reactions to drugs. N. Engl. J. Med. 1994; 331:
1272–85.
13 Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classifi-
cation of cases of toxic epidermal necrolysis, Stevens–
Johnson syndrome, and erythema multiforme. Arch.
Dermatol. 1993; 129: 92–6.
14 Tanaka N, Kimura H, Iida K et al. Quantitative analysis
of cytomegalovirus load using a real-time PCR assay.
J. Med. Virol. 2000; 60: 455–62.
15 Tanaka N, Kimura H, Hoshino Y et al. Monitoring four
herpesviruses in unrelated cord blood transplantation.
Bone Marrow Transplant. 2000; 26: 1193–7.
16 Aihara Y, Ito S, Kobayashi Y et al. Carbamazepine-
induced hypersensitivity syndrome associated with
transient hypogammaglobulinemia and reactivation of
human herpesvirus 6 infection demonstrated by real-time
quantitative PCR. Br. J. Dermatol. 2003; 149: 27–33.
17 Le Cleach L, Fillet AN, Agut H et al. Human herpesviruses
6 and 7. Arch. Dermatol. 1998; 34: 1155–7.
18 Waranabe T, Kawamura T, Jacob SE et al. Pityriasis rosea
is associated with systemic active infection with both
human herpesvirus-7 and human herpesvirus-6. J. Invest.
Dermatol. 2002; 119: 793–979.
19 Lusso P, Secchiero P, Crowley RW et al. CD4 is a critical
component of the receptor for human herpesvirus 7:
Interference with human immunodeficiency virus. Proc.
Natl Acad. Sci. USA 1994; 91: 3872–6.
20 Tanaka-Taya K, Kondo T, Nakagawa N et al. Reactiva-
tion of human herpesvirus 6 by infection of human
herpesvirus 7. J. Med. Virol. 2000; 60: 284–9.
21 Yoshikawa T, Suga S, Asano Y et al. Human herpesvirus-6
infection in bone marrow transplantation. Blood 1991;
78: 1381–4.
22 van Ginneken EEM, van der Meer JWM, Netten PM. A
man with a mysterious hypogammaglobulinemia and skin
rash. Neth. J. Med. 1999; 54: 158–62.
23 Dosch HM, Jason J, Gelfand EW. Transient antibody
deficiency and abnormal T suppressor cells induce by
phenytoin. N .Engl. J. Med. 1982; 7: 406–9.
24 Ishizaka A, Nakanishi M, Kasahara E et al. Phenytoin-
induced IgG2 and IgG4 deficiencies in a patient with
epilepsy. Acta Paediatr. 1992; 81: 646–8.
25 Mauri-Hellweg D, Bettens F, Mauri D et al. Activation of
drug-specific CD4+ and CD8+ T cells in individuals
allergic to sulfonamides, phenytoin, and carbamazepine.
J. Immunol. 1995; 155: 462–72.
26 Shear NH, Spielberg SP. Anticonvulsant hypersensitivity
syndrome. In vitro assessment of risk. J. Clin. Invest.
1988; 82: 1826–32.
27 Leeder JS, Gaedigk A, Lu X et al. Epitope mapping studies
with human anti-cytochrome P450 3A3A antibodies. Mol.
Pharmacol. 1996; 49: 234–43.
28 Galindo Bonilla PA, Romero Aguilera G, Feo Brito F et al.
Phenytoin hypersensitivity syndrome with positive patch
test. A possible cross-reactivity with amitriptyline. Invest.
Allergol. Clin. Immunol. 1998; 8: 186–90.
 
